論文 - 詳細
| RRC ID | 87300 |
|---|---|
| 著者 | Kamei N, Hashimoto A, Tanaka E, Murata K, Yamaguchi M, Yokoyama N, Kato M, Oki K, Saito T, Saido TC, Takeda-Morishita M. |
| タイトル | Therapeutic effects of anti-amyloid β antibody after intravenous injection and efficient nose-to-brain delivery in Alzheimer's disease mouse model. |
| ジャーナル | Drug Deliv Transl Res |
| Abstract |
Antibody drugs that target amyloid β (Aβ) are considered possible treatments for Alzheimer's disease; however, most have been dropped from clinical trials. We hypothesized that administration route for antiAβ antibody (AntiAβ) might affect its therapeutic potential and thus compared delivery of antibodies to the brain and their effect on cognitive dysfunction and amyloid disposition via intravenous (i.v.) and intranasal routes with and without the cell-penetrating peptide, L-penetratin. We demonstrated that intranasal administration with L-penetratin more efficiently delivered human immunoglobulin G (IgG), a model molecule for AntiAβ, to the brain compared with i.v. injection. We found that multiple intranasal treatments with Alexa 594-labeled AntiAβ (A594-AntiAβ) with L-penetratin significantly improved learning by mice with aged amyloid precursor protein (APP) knock-in (App KI mice). Further, intranasal administration of A594-AntiAβ increased the amount of soluble Aβ (1-42) in the brain, suggesting suppression of Aβ aggregation in insoluble form and involvement of activated microglia in Aβ clearance. Thus, administration route may be critical for efficient delivery of AntiAβ to the brain, and the nose-to-brain delivery with L-penetratin can maximize its therapeutic efficacy. |
| 巻・号 | 12(11) |
| ページ | 2667-2677 |
| 公開日 | 2022-11-1 |
| DOI | 10.1007/s13346-022-01117-6 |
| PII | 10.1007/s13346-022-01117-6 |
| PMID | 35015254 |
| MeSH | Aged Alzheimer Disease* / drug therapy Amyloid beta-Peptides / metabolism Amyloid beta-Protein Precursor / metabolism Amyloid beta-Protein Precursor / pharmacology Amyloid beta-Protein Precursor / therapeutic use Animals Brain / metabolism Cell-Penetrating Peptides* Disease Models, Animal Humans Immunoglobulin G / metabolism Injections, Intravenous Mice |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | News |
| 各媒体での言及数の合計 | 2 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| 実験動物マウス | RBRC06344 |